vs

Side-by-side financial comparison of CrossAmerica Partners LP (CAPL) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

CrossAmerica Partners LP is the larger business by last-quarter revenue ($866.3M vs $487.7M, roughly 1.8× CLOVER HEALTH INVESTMENTS, CORP.). CrossAmerica Partners LP runs the higher net margin — 1.2% vs -10.1%, a 11.3% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -8.3%). CrossAmerica Partners LP produced more free cash flow last quarter ($22.4M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -4.1%).

TowerBrook Capital Partners, L.P. is an investment management firm headquartered in London and New York City. TowerBrook spun out of Soros Fund Management in 2005 and became known for acquiring majority stakes in companies such as Jimmy Choo. Managing $25+ billion in a number of private equity funds and structured opportunities funds, TowerBrook listed 110 investments on its website as of 2025.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

CAPL vs CLOV — Head-to-Head

Bigger by revenue
CAPL
CAPL
1.8× larger
CAPL
$866.3M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+53.0% gap
CLOV
44.7%
-8.3%
CAPL
Higher net margin
CAPL
CAPL
11.3% more per $
CAPL
1.2%
-10.1%
CLOV
More free cash flow
CAPL
CAPL
$91.3M more FCF
CAPL
$22.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-4.1%
CAPL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CAPL
CAPL
CLOV
CLOV
Revenue
$866.3M
$487.7M
Net Profit
$10.2M
$-49.3M
Gross Margin
12.4%
Operating Margin
3.0%
-10.1%
Net Margin
1.2%
-10.1%
Revenue YoY
-8.3%
44.7%
Net Profit YoY
-39.6%
-123.2%
EPS (diluted)
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAPL
CAPL
CLOV
CLOV
Q4 25
$866.3M
$487.7M
Q3 25
$971.8M
$496.6M
Q2 25
$961.9M
$477.6M
Q1 25
$862.5M
$462.3M
Q4 24
$944.2M
$337.0M
Q3 24
$1.1B
$331.0M
Q2 24
$1.1B
$356.3M
Q1 24
$941.5M
$346.9M
Net Profit
CAPL
CAPL
CLOV
CLOV
Q4 25
$10.2M
$-49.3M
Q3 25
$13.6M
$-24.4M
Q2 25
$25.2M
$-10.6M
Q1 25
$-7.1M
$-1.3M
Q4 24
$16.9M
$-22.1M
Q3 24
$10.7M
$-9.2M
Q2 24
$12.4M
$7.4M
Q1 24
$-17.5M
$-19.2M
Gross Margin
CAPL
CAPL
CLOV
CLOV
Q4 25
12.4%
Q3 25
10.8%
Q2 25
10.5%
Q1 25
10.4%
Q4 24
10.7%
Q3 24
10.3%
24.5%
Q2 24
9.2%
30.3%
Q1 24
8.6%
23.6%
Operating Margin
CAPL
CAPL
CLOV
CLOV
Q4 25
3.0%
-10.1%
Q3 25
2.9%
-4.9%
Q2 25
4.3%
-2.2%
Q1 25
0.2%
-0.3%
Q4 24
3.0%
-6.4%
Q3 24
2.5%
-2.7%
Q2 24
2.5%
2.0%
Q1 24
-1.4%
-6.5%
Net Margin
CAPL
CAPL
CLOV
CLOV
Q4 25
1.2%
-10.1%
Q3 25
1.4%
-4.9%
Q2 25
2.6%
-2.2%
Q1 25
-0.8%
-0.3%
Q4 24
1.8%
-6.6%
Q3 24
1.0%
-2.8%
Q2 24
1.1%
2.1%
Q1 24
-1.9%
-5.5%
EPS (diluted)
CAPL
CAPL
CLOV
CLOV
Q4 25
$0.24
Q3 25
$0.34
Q2 25
$0.64
Q1 25
$-0.20
Q4 24
$0.42
Q3 24
$0.27
Q2 24
$0.31
Q1 24
$-0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAPL
CAPL
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$3.1M
$78.3M
Total DebtLower is stronger
$687.2M
Stockholders' EquityBook value
$308.7M
Total Assets
$964.7M
$541.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAPL
CAPL
CLOV
CLOV
Q4 25
$3.1M
$78.3M
Q3 25
$5.8M
Q2 25
$9.7M
Q1 25
$6.7M
Q4 24
$3.4M
$194.5M
Q3 24
$7.8M
$288.0M
Q2 24
$5.5M
$254.8M
Q1 24
$6.3M
$208.3M
Total Debt
CAPL
CAPL
CLOV
CLOV
Q4 25
$687.2M
Q3 25
$700.8M
Q2 25
$722.7M
Q1 25
$774.1M
Q4 24
$763.9M
Q3 24
$769.2M
Q2 24
$786.7M
Q1 24
$795.8M
Stockholders' Equity
CAPL
CAPL
CLOV
CLOV
Q4 25
$308.7M
Q3 25
$340.9M
Q2 25
$344.2M
Q1 25
$336.1M
Q4 24
$341.1M
Q3 24
$342.2M
Q2 24
$324.9M
Q1 24
$292.5M
Total Assets
CAPL
CAPL
CLOV
CLOV
Q4 25
$964.7M
$541.0M
Q3 25
$998.9M
$559.7M
Q2 25
$1.0B
$575.0M
Q1 25
$1.1B
$583.7M
Q4 24
$1.1B
$580.7M
Q3 24
$1.1B
$653.0M
Q2 24
$1.2B
$674.2M
Q1 24
$1.2B
$671.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAPL
CAPL
CLOV
CLOV
Operating Cash FlowLast quarter
$29.4M
$-66.9M
Free Cash FlowOCF − Capex
$22.4M
$-69.0M
FCF MarginFCF / Revenue
2.6%
-14.1%
Capex IntensityCapex / Revenue
0.8%
0.4%
Cash ConversionOCF / Net Profit
2.89×
TTM Free Cash FlowTrailing 4 quarters
$55.8M
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAPL
CAPL
CLOV
CLOV
Q4 25
$29.4M
$-66.9M
Q3 25
$24.4M
$12.1M
Q2 25
$22.6M
$5.4M
Q1 25
$15.0M
$-16.3M
Q4 24
$11.1M
$34.8M
Q3 24
$41.9M
$50.0M
Q2 24
$28.9M
$44.8M
Q1 24
$5.8M
$25.9M
Free Cash Flow
CAPL
CAPL
CLOV
CLOV
Q4 25
$22.4M
$-69.0M
Q3 25
$17.7M
$11.4M
Q2 25
$10.8M
$4.8M
Q1 25
$4.9M
$-16.5M
Q4 24
$3.9M
$33.3M
Q3 24
$34.2M
$49.6M
Q2 24
$23.6M
$44.4M
Q1 24
$-289.0K
$25.5M
FCF Margin
CAPL
CAPL
CLOV
CLOV
Q4 25
2.6%
-14.1%
Q3 25
1.8%
2.3%
Q2 25
1.1%
1.0%
Q1 25
0.6%
-3.6%
Q4 24
0.4%
9.9%
Q3 24
3.2%
15.0%
Q2 24
2.1%
12.5%
Q1 24
-0.0%
7.3%
Capex Intensity
CAPL
CAPL
CLOV
CLOV
Q4 25
0.8%
0.4%
Q3 25
0.7%
0.1%
Q2 25
1.2%
0.1%
Q1 25
1.2%
0.0%
Q4 24
0.8%
0.5%
Q3 24
0.7%
0.1%
Q2 24
0.5%
0.1%
Q1 24
0.6%
0.1%
Cash Conversion
CAPL
CAPL
CLOV
CLOV
Q4 25
2.89×
Q3 25
1.79×
Q2 25
0.90×
Q1 25
Q4 24
0.66×
Q3 24
3.92×
Q2 24
2.33×
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CAPL
CAPL

Retail Segment$505.3M58%
Wholesale$360.9M42%
Other$1.2M0%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons